Sodium Bicarbonate for Injection Recalled to Hospital Pharmacy Level

New Enzyme Replacement Therapy Approved for Pompe Disease
August 6, 2021
Moderna, Pfizer/BioNTech COVID-19 Vaccines Authorized for Use as Booster Shots for Immunocompromised Individuals
August 12, 2021
New Enzyme Replacement Therapy Approved for Pompe Disease
August 6, 2021
Moderna, Pfizer/BioNTech COVID-19 Vaccines Authorized for Use as Booster Shots for Immunocompromised Individuals
August 12, 2021

Sodium Bicarbonate for Injection Recalled to Hospital Pharmacy Level

August 10, 2021 – SterRx, LLC, has recalled three lots of Sodium Bicarbonate in 5% Dextrose Injection 150mEq per 1,000mL to the hospital pharmacy level as a result of waterborne microbial contamination.

Sodium bicarbonate injection is indicated to treat high potassium levels, irregular heartbeat, and excess acid levels in the body’s fluids. The recalled product is meant to be sterile. Administering a product that is not sterile but is intended to be could cause local infections or potentially life-threatening systemic infections.

SterRx is notifying customers of the recall and advising them to quarantine, discontinue distribution, and return any sodium bicarbonate injection belonging to the affected lots. Patients who may have experienced problems that may be related to use of the recalled product should contact their healthcare provider. Adverse events can be reported to the U.S. FDA’s MedWatch program.

A copy of the full recall notice is available on the FDA’s website.

There is no impact to members through Benecard Central Fill.